Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Tularik Inc. (TLRK) -- Ignore unavailable to you. Want to Upgrade?

To: Czechsinthemail who wrote (342)	10/28/2002 1:54:34 PM
From: Czechsinthemail	Respond to of 598

TLRK's presentation at the Salomon Smith Barney 2002 Global Health Care Conference is definitely worth a listen, particularly for information about the new developments in their pipeline. Returning Andrew Perlman gave the presentation. They are planning for a new IND this quarter that should be coming from one of the following: T659 for lipid disorders. It increases HDL (good) cholesterol and is intented for use in conjunction with statins. T3131 for diabetes. This one is targeted for Type II diabetes. Perlman said it provides equal glucose reduction with fewer side effects, specifically no edema, no anemia and no cardiovascular swelling. T792 for obesity. Provides appetite suppression. Perlman also gave more background on T67, T607 and T487, which are already in clinical trials. He said that T67 was "extraordinarily well tolerated" and discussed the advantages of the irreversible binding of beta tubulin. Perlman also emphasized TLRK's "sustainable pipeline" as a particular strength. He discussed TLRK's proprietary RDA approach for scanning the genome for novel oncogenes. There are lots of targets and leads being discovered, so there is less dependence on the results of any one drug candidate. It reinforces the "big picture" case for the company developing multiple avenues of success over time. On the financial side, they are expecting higher revenues from a new partnership before year end. Here is the URL for the conference replay: veracast.com